Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities
SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted by the GMP MED office of the Agenzia Italiana del Farmaco (AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament.
In the European Union, national competent authorities - AIFA in Italy - are responsible for inspecting manufacturing sites based within their own territories. Sites located in one European Member State also benefit from mutual recognition agreements (MRAs) that the European Commission has signed with the authorities of the United States, Switzerland, Canada, Israel, Australia, Japan and New Zealand concerning the conformity assessment of medicinal products.
Philogen plant in Rosia was designed in accordance with the new Annex 1 of the Rules Governing Medicinal Products in the European Union for Good Manufacturing Practice of Medicinal Products for Human Use. The site plans to produce therapeutic proteins in mammalian cells, with a focus on the company’s immunocytokines such as Nidlegy™, for both clinical trials and commercial purposes. The completion of the facility required an investment of over 15 million Euros.
On 16 October 2023, Philogen had announced positive topline results from the Phase III trial of Nidlegy™ in patients with locally advanced fully resectable melanoma (NCT02938299). The Rosia facility will manufacture commercial supplies of Nidlegy™ and has been structured to address a global distribution of the product.
Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: "Following the positive readout of Nidlegy™ Phase III trial, we are very pleased that our new manufacturing site in Rosia has received the GMP Certificate by AIFA. This represents an additional important milestone toward turning Philogen from research to a commercial company.”
Dr. Duccio Neri, co-founder and Executive Chairman of Philogen, commented: "We are excited that our new manufacturing facility is now poised for supplying life-saving medicines to patients who are in need. This achievement has been possible thanks to multi-million euros investments to construct the new state-of-the-art GMP facility. The new facility in Rosia is among the very few ones in Italy that is planned and equipped to manufacture GMP-grade therapeutic proteins in mammalian cells. We are proud that Philogen has, over the last few years, devoted significant efforts and resources to expand its production capacity and has hired a high number of new talented people in the Italian territory.”
Philogen (https://www.philogen.com) is an Italian-Swiss biotechnology company specialized in the research and development of innovative pharmaceuticals for the treatment of cancer. The Group's main therapeutic strategy is based on the use of ligands capable to selectively deliver potent payloads (such as pro-inflammatory cytokines, drugs or radionuclides) to the tumor mass, sparing healthy tissues. Over the years, Philogen has discovered and developed monoclonal antibody- and small molecule-based ligands with high affinity to tumor-associated antigens. The Group is headquartered in Siena, Italy, with a subsidiary and research center in Zurich, Switzerland. In addition to its main oncology focus, Philogen is also active in the development of novel pharmaceuticals for the treatment of chronic and debilitating conditions.
FOR MORE INFORMATION:
Philogen - Investor Relations
IR@philogen.com - Emanuele Puca | Investor RelationsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Equinor ASA: Buy-back of shares to share programmes for employees21.2.2024 09:40:58 CET | Press release
Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management. Date on which the buy-back programme was announced: 7 February 2024. The duration of the buy-back programme: 15 February 2024 to 15 January 2025. Size of the buy-back programme: The total purchase amount under the programme is NOK 1,156,000,000 and the maximum shares to be acquired is 16,800,000 shares, of which up to 7,400,000 shares can be acquired in the period from 15 February 2024 to 15 May 2024, and up to 9,400,000 shares can be acquired in the period from 16 May 2024 to 15 January 2025. On 15 February 2024, Equinor ASA has purchased a total of 693,724 own shares at the Oslo Stock Exchange at an average price of NOK 259.4690 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK) Total transaction
Equinor ASA: Kjøp av aksjer til aksjeprogram for ansatte21.2.2024 09:40:58 CET | Pressemelding
Nedenfor følger informasjon om transaksjoner knyttet til tilbakekjøpsprogrammet for Equinor ASA (OSE:EQNR, NYSE:EQNR) til bruk i aksjebaserte insentivprogrammer for ansatte og ledelse. Dato for annonsering av tilbakekjøpsprogrammet: 7. februar 2024. Varighet av tilbakekjøpsprogrammet: 15. februar 2024 til 15. januar 2025. Størrelse av tilbakekjøpsprogrammet: Samlet kjøpesum i tilbakekjøpsprogrammet er inntil NOK 1.156.000.000 og det maksimale antall aksjer som kan erverves er 16.800.000, hvorav opp til 7.400.000 aksjer kan erverves i perioden fra 15. februar 2024 til 15. mai 2024, og opptil 9.400.000 aksjer kan erverves i perioden fra 16. juni 2024 til 15. januar 2025. Den 15. februar 2024 kjøpte Equinor ASA totalt 693.724 egne aksjer ved Oslo Børs til en gjennomsnittspris på NOK 259,4690 pr. aksje. Oversikt over transaksjoner: DateAggregert volum (antall aksjer)Vektet gjennomsnittspris pr. aksje (NOK)Total transaksjonsverdi (NOK)15 februar 2024693.724259,4690179.999.873Totalt tidliger
Cortus Energy AB offentliggör tidplan för sammanläggning av aktier21.2.2024 09:33:51 CET | Pressemelding
Vid den extra bolagsstämman i Cortus Energy AB ("Cortus Energy" eller "Bolaget") den 24 januari 2024 beslutades att genomföra en sammanläggning av aktier 1:100, innebärande att etthundra (100) aktier läggs samman till en (1) ny aktie. Stämman bemyndigade styrelsen att fastställa avstämningsdag för sammanläggningen. Styrelsen i Cortus Energy har, i enlighet med årsstämmans beslut, fastställt att avstämningsdag ska vara den 28 februari 2024. Sista dagen för handel i Cortus Energys aktie innan sammanläggningen är den 26 februari 2024 och första dagen för handel i Cortus Energys aktie efter sammanläggningen är den 27 februari 2024. Cortus Energys aktiekurs kommer därmed att återspegla effekten av sammanläggningen från och med den 27 februari 204. Genom sammanläggningen kommer det totala antalet aktier i Bolaget att minska från 2 149 896 400 aktier till 21 498 964 aktier. Till följd av sammanläggningen kommer Cortus Energys aktie från och med den 27 februari 2024 att byta ISIN-kod. Den nya
Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position21.2.2024 09:30:00 CET | Press release
BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500.000, pursuant to the terms and conditions of the Financing Agreement between BBS and RiverFort Global Opportunities Pcc Limited (“RiverFort”) signed and announced on September 30th 2021. BBS settles the transaction fee of EUR 45,000 by the transfer of 74,915 treasury shares at the price of EUR 0.6007 per share. The reference price as agreed in the terms and conditions of the original agreement is the average of the daily VWAP for each the five consecutive trading day prior to the date of Advance (the “Reference Price”). Following the drawdown of the advance BBS will issue 416,195 warrants to RiverFort (with 0.8410
Nr. 1/2024 - Finanskalender 2024/202521.2.2024 09:27:27 CET | pressemeddelelse
Nasdaq Copenhagen Nikolaj Plads 6 DK-1067 Copenhagen K København, 21 februar 2024 SELSKABSMEDDELELSE nr. 1/2024 FINANSKALENDER 2024/2025 Selskabets finanskalender for 2024/2025 er fastlagt som følger: 2024: 21.02.2024 Årsrapport 2023 21.03.2024 Ordinær generalforsamling 29.08.2024 Delårsrapport, første halvår 2025: 25.02.2025 Årsrapport 2024 26.03.2025 Ordinær generalforsamling Cemat A/S Frede Clausen Bestyrelsesformand Denne selskabsmeddelelse er udarbejdet på dansk og engelsk. I tvivlstilfælde er den danske udgave gældende. Vedhæftet fil Selskabsmeddelelse nr. 1 - 21.02.2024 - Finanskalender